FLT3 and acute myeloid leukemia: Indeed, in 2017, the FDA approved the FLT3 inhibitor midostaurin in combination with standard of care chemotherapy for the treatment of newly-diagnosed FLT3-mutant AML patients [36], superseding an era of very little advancement in AML therapy [37].